Ventricular Fibrillation (VF)

Definition and Pathophysiology

Ventricular fibrillation (VF) represents the most severe and catastrophic manifestation of ventricular tachyarrhythmia. The cardiac rhythm becomes exceedingly rapid (>300 beats per minute), chaotic, and disorganized, leading to a complete cessation of coordinated mechanical ventricular contraction and an immediate loss of forward blood flow. Absent immediate intervention, death ensues within a few minutes. VF constitutes the primary electrophysiological mechanism underlying sudden cardiac death (SCD). It is distinct from ventricular asystole (the isoelectric flatline), as VF maintains uncoordinated intrinsic electrical activity within the ventricular myocardium, notwithstanding its total failure to generate physical myocardial contraction.

Etiology and Predisposing Factors

The underlying etiologies of VF encompass all pathological substrates and clinical conditions capable of precipitating sudden cardiac death via arrhythmogenic mechanisms. These primarily include:

  • Acute myocardial infarction or acute myocardial ischemia.
  • Cardiomyopathy and acute myocarditis.
  • Hypertrophic cardiomyopathy (HCM).
  • Valvular heart disease and congenital heart defects.
  • Inherited primary arrhythmia syndromes / channelopathies (e.g., Brugada syndrome, Long QT syndrome, etc.).
  • Severe electrolyte imbalances and systemic metabolic disturbances.
  • Proarrhythmic drug toxicity.
  • Physical triggers and external trauma (e.g., electrocution, commotio cordis).

Furthermore, VF frequently manifests as the terminal, cataclysmic event in patients progressing through the end-stage phases of chronic structural heart disease culminating in refractory congestive heart failure.

Therapeutic Management and Clinical Interventions

The definitive acute treatment for VF is immediate electrical defibrillation using an external defibrillator to deliver a high-energy shock across the myocardium, allowing the physiological sinus node to re-establish a stable cardiac rhythm [2]. The probability of successful rhythm restoration degrades exponentially with every minute of delay [2]. Concurrently, high-quality cardiopulmonary resuscitation (CPR) must be initiated until defibrillation is accessible.

Following successful resuscitation, the patient must undergo an exhaustive diagnostic evaluation to identify the specific underlying etiologies [2]. Once diagnosed, comprehensive secondary prevention strategies must be implemented to mitigate the future risk of recurrent sudden cardiac death, including:

  • Pharmacotherapy: Optimizing medical management with beta-blockers, angiotensin-converting enzyme inhibitors (ACE inhibitors), and statins.
  • Device Therapy: Surgical implantation of an implantable cardioverter-defibrillator (ICD) or biventricular systems.
  • Surgical Interventions: Myocardial revascularization (bypass grafting) or surgical correction of valvular pathology.

Over recent years, substantial clinical and technological advancements targeting risk stratification and device therapy have significantly improved the long-term prognosis, leading to a quantifiable increase in overall life expectancy among cardiovascular patients.

2026-11-18T22:37:39+00:00